Evaluation of a Conditioning Regimen of Post-Transplant Cyclophosphamide and Sirolimus with or without CTLA4-Ig in a Mismatched Murine Model

Hematopoietic stem cell transplant (HSCT) is the only curative option available for patients living with sickle cell disease (SCD). Stable mixed chimerism is sufficient to reverse the sickle phenotype. The current conditioning regimen of post-transplant cyclophosphamide (PT-Cy) and sirolimus (Sir) has proven to synergistically induce stable mixed chimerism.1 The mechanism of tolerance is not fully understood. Previous studies demonstrated that a combination of Sir and abatacept (CTLA4-Ig) promotes tolerance and prolongs allograft survival.

Source: Biology of Blood and Marrow Transplantation - January 31, 2019 Category: Hematology Authors: Katherine Almengo, Purevdorj B. Olkhanud, Courtney D. Fitzhugh Tags: 266 Source Type: research